AML-432 Overall Survival (OS) by Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant- Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial
AML-432 Overall Survival (OS) by Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant- Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial
复制标题
AML-432 突变等位基因（R140 或 R172）在随机、开放性研究中接受 Enasidenib 或常规治疗方案 (CCR) 治疗的晚期、突变复发/难治性急性髓系白血病 (AML) 患者的总生存 (OS)
DOI：
10.1016/s2152-2650(22)01293-9
复制
发表时间：
2022
影响因子：
2.7
通讯作者：
DiNardo C
中科院分区：
文献类型：
--
作者：
DiNardo C
